Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial

American Journal of Medicine

Volumn 129, Issue 8, 2016, Pages 850-857.e2

  Giugliano, Robert P ^a   Ruff, Christian T ^a   Wiviott, Stephen D ^a   Nordio, Francesco ^a   Murphy, Sabina A ^a   Kappelhof, Johannes A N ^b   Shi, Minggao ^b   Mercuri, Michele F ^b   Antman, Elliott M ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Anticoagulant; Bleeding; Death; Edoxaban; Factor Xa inhibitor; Hemorrhage; Warfarin

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ARTERY EMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EXTRACRANIAL BLEEDING; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR BLEEDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOCK; SUDDEN CARDIAC DEATH; AGED; COMPARATIVE STUDY; MORTALITY; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; PYRIDINES; THIAZOLES; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84975691196     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.02.028     Document Type: Article

References (25)

1. 1 Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129 (2014), 837–847.
2. 2 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
3. 3 Connolly, S., Pogue, J., Hart, R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006), 1903–1912.
4. 4 Senoo, K., Lip, G.Y., Lane, D.A., Buller, H.R., Kotecha, D., Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: Amadeus trial. Stroke 46 (2015), 2523–2528.
5. 5 Goldstein, J.N., Refaai, M.A., Milling, T.J. Jr., et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 385 (2015), 2077–2087.
6. 6 Dowlatshahi, D., Butcher, K.S., Asdaghi, N., et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 43 (2012), 1812–1817.
7. 7 Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
8. 8 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
9. 9 Ruff, C.T., Giugliano, R.P., Antman, E.M., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160 (2010), 635–641.
10. 10 Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
11. 11 Schulman, S., Kearon, C., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005), 692–694.
12. 12 Giugliano, R.P., Giraldez, R.R., Morrow, D.A., et al. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the EXTRACT-TIMI 25 trial. Eur Heart J 31 (2010), 2103–2110.
13. 13 Healey, J.S., Eikelboom, J., Douketis, J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 126 (2012), 343–348.
14. 14 Sherwood, M.W., Douketis, J.D., Patel, M.R., et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 129 (2014), 1850–1859.
15. 15 Marijon, E., Le Heuzey, J.Y., Connolly, S., et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 128 (2013), 2192–2201.
16. 16 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
17. 17 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
18. 18 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
19. 19 Hylek, E.M., Held, C., Alexander, J.H., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 63 (2014), 2141–2147.
20. 20 Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
21. 21 JSC Joint Working Group, Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 78 (2014), 1997–2021.
22. 22 Crowther, M., Crowther, M.A., Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol 35 (2015), 1736–1745.
23. 23 Lip, G.Y., Skjøth, F., Nielsen, P.B., Larsen, T.B., Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 114 (2015), 826–834.
24. 24 Lip, G.Y., Skjøth, F., Rasmussen, L.H., Larsen, T.B., Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 65 (2015), 1385–1394.
25. 25 Dlott, J.S., George, R.A., Huang, X., et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 129 (2014), 1407–1414.